Genmab A/S Stock

Genmab A/S CapEx/D&A

The CapEx to Depreciation Ratio of Genmab A/S (GMAB.CO) as of Aug 13, 2026 is 1.02. In the previous year, CapEx to Depreciation Ratio was 0.98 — a change of 4.20% (higher).

CapEx/D&A

1.02

YoY

4.20%

Last updated:

CapEx to Depreciation Ratio of Genmab A/S is 2026 1.02 . CapEx to Depreciation Ratio of Genmab A/S was 2025 0.98 . It decreases by 4.20% higher compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

CapEx to Depreciation Ratio of Genmab A/S is 1.02 in 2026.

CapEx to Depreciation Ratio of Genmab A/S changed from 0.98 to 1.02, representing a 4.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Genmab A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

Cash Flow — Genmab A/S

All Key Metrics — Genmab A/S